🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the effort against superbug strains of the pathogen, according to health experts.

A Global Challenge

Cases of gonorrhoea are increasing globally, with data suggesting more than 82 million infections per year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

Zoliflodacin, also known as a brand name, was cleared by the US FDA in recent days for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in the same week. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization signifies a major breakthrough in the management of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Results and Global Access

According to results published in a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This establishes an equal footing with the typical regimen, which involves an injection and a pill. The research included hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the authority to make available and distribute the drug in a wide range of developing nations.

Clinicians treating patients have voiced optimism. Having a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is considered essential to lessen the impact of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.